Schrodinger, Inc.
- Last sale
- Nov 12, 2026 · -2.05%
- Market cap
- $2.32B
- 75.08M shares
- Filings
- 546
Q3 2026+23.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+56.5% FY25 yoy
- $2.32B
- —
- 8.6×
- 7.7×
- -5.04%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $255,869,000 | reported | |
| FY 2024 | 2024-12-31 | $207,539,000 | reported | |
| FY 2023 | 2023-12-31 | $216,666,000 | reported | |
| FY 2022 | 2022-12-31 | $180,955,000 | reported | |
| FY 2021 | 2021-12-31 | $137,931,000 | reported | |
| FY 2020 | 2020-12-31 | $108,095,000 | reported | |
| FY 2019 | 2019-12-31 | $85,543,000 | reported |
Segments
LineFY2025ShareChange
Software$199.50M78%+10.6%
Drug discovery$56.37M22%+107.4%
Total$255.87M
Pharmaceutical preparations
Schrodinger, Inc. is the 76th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
HROWHarrow, Inc.$272.3M36.4%1.9%$1.1BVREOFVireo Growth Inc.$268.8M170.4%25.3%$439.7MLGNDLigand Pharmaceuticals Inc$268.1M60.4%46.4%$6.3BARVNArvinas, Inc.$262.6M0.3%30.8%$493.4M
SDGRSchrodinger, Inc. (this company)$255.9M23.3%40.4%$2.3B
RCUSArcus Biosciences, Inc.$247.0M4.3%142.9%$2.6BKROSKeros Therapeutics, Inc.$244.1M6,775.0%35.7%$197.2MAKBAAkebia Therapeutics, Inc.$236.2M47.5%2.3%$138.5MANABAnaptysbio, Inc$234.6M157.0%5.6%$1.4BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Schrodinger, Inc. · CIK 1490978 · Engraved from SEC EDGAR